PCSK9 inhibiting single-domain antibodies (University of Montreal)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePCSK9 inhibiting single-domain antibodies (University of Montreal)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversite De Montreal
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversite De MontrealUnivalor
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A